Phenotypic discordance between primary and metastatic breast cancer (MBC) in a large scale real-life multicentre French cohort

Congress : SABCS

Authors : Sarah Lefèvre, Amélie Lusque, Natacha Joyon, et al.

Experts group or program : ESMÉ - données de vie réelle en cancérologie

Therapeutic options at diagnosis for metastatic breast cancers (MBC) differ largely according to cancer phenotype (namely, hormone receptor (HR) and HER2 status). Reported discordance rates between primary tumor and metastasis vary widely in literature, with a median of 18% for estrogen receptor, 31% for progesterone receptor and 10% for HER2. The present study aimed to compare phenotypic profiles between primary and MBC in the real-life setting.

En savoir plus